



- (51) **International Patent Classification:**
A61K 31/573 (2006.01) *A61K 47/69* (2017.01)
- (21) **International Application Number:**
PCT/US2024/026982
- (22) **International Filing Date:**
30 April 2024 (30.04.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/463,113 01 May 2023 (01.05.2023) US
- (71) **Applicant:** AIMMAX THERAPEUTICS, INC.
[US/US]; 4220 Apex Highway, Suite 140, Durham, North Carolina 27713 (US).
- (72) **Inventors:** WANG, Laurene; 4220 Apex Highway, Suite 140, Durham, North Carolina 27713 (US). NUNEZ, Derek J.; 4220 Apex Highway, Suite 140, Durham, North Carolina 27713 (US). COOK, Jason B.; 4220 Apex Highway, Suite 140, Durham, North Carolina 27713 (US). LIAW, Wayne W-C; 5409 Harvest Run Drive, San Diego, California 92130 (US).
- (74) **Agent:** MCLAREN, Kevin; 101 West Kirkwood Avenue, Suite 238, Bloomington, Indiana 47404 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— of inventorship (Rule 4.17(iv))

(54) **Title:** CORTICOSTEROID NANOSUSPENSIONS AND USES THEREOF




FIG. 2

(57) **Abstract:** Suspension formulations of nanoparticles of clobetasol propionate are described. The suspensions can be used therapeutically to treat skin and ocular burns; to enhance wound healing; to prevent or reduce hypertrophic scarring/keloids; to treat allergic rhinitis/sinusitis, asthma, inner ear disorders including hearing loss, tinnitus, or vertigo, tenosynovitis, tendinitis, enthesitis or arthritis.

[Continued on next page]

Published:

- *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*